Dominion Energy (NYSE:D) Updates FY 2024 Earnings Guidance
by Scott Moore · The Cerbat GemDominion Energy (NYSE:D – Get Free Report) updated its FY 2024 earnings guidance on Friday. The company provided EPS guidance of 2.680-2.830 for the period, compared to the consensus EPS estimate of 2.770. The company issued revenue guidance of -. Dominion Energy also updated its FY 2025 guidance to 3.250-3.540 EPS.
Dominion Energy Trading Down 2.5 %
D stock traded down $1.48 during mid-day trading on Monday, reaching $57.51. 3,337,204 shares of the stock traded hands, compared to its average volume of 4,395,503. The business has a 50-day moving average price of $57.87 and a two-hundred day moving average price of $54.14. The stock has a market capitalization of $48.25 billion, a PE ratio of 31.05, a PEG ratio of 1.58 and a beta of 0.59. The company has a debt-to-equity ratio of 1.42, a quick ratio of 0.78 and a current ratio of 0.93. Dominion Energy has a one year low of $43.53 and a one year high of $61.97.
Dominion Energy (NYSE:D – Get Free Report) last posted its quarterly earnings data on Friday, November 1st. The utilities provider reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.06. The company had revenue of $3.94 billion for the quarter, compared to analyst estimates of $4.18 billion. Dominion Energy had a net margin of 11.63% and a return on equity of 7.69%. The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.77 EPS. Equities research analysts expect that Dominion Energy will post 2.76 EPS for the current year.
Dominion Energy Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 20th. Shareholders of record on Friday, November 29th will be given a $0.6675 dividend. This represents a $2.67 annualized dividend and a yield of 4.64%. The ex-dividend date is Friday, November 29th. Dominion Energy’s dividend payout ratio (DPR) is presently 140.53%.
Wall Street Analysts Forecast Growth
D has been the topic of a number of research analyst reports. Jefferies Financial Group started coverage on shares of Dominion Energy in a report on Friday, September 20th. They issued a “hold” rating and a $58.00 price target on the stock. BMO Capital Markets upped their target price on shares of Dominion Energy from $53.00 to $57.00 and gave the stock a “market perform” rating in a research note on Monday, August 5th. Barclays raised their target price on shares of Dominion Energy from $54.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 15th. JPMorgan Chase & Co. boosted their price target on Dominion Energy from $54.00 to $57.00 and gave the company a “neutral” rating in a report on Monday, August 12th. Finally, Scotiabank raised their price objective on Dominion Energy from $48.00 to $58.00 and gave the stock a “sector perform” rating in a report on Tuesday, August 20th. Nine equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Dominion Energy has a consensus rating of “Hold” and a consensus target price of $55.40.
Read Our Latest Research Report on Dominion Energy
Dominion Energy Company Profile
Dominion Energy, Inc produces and distributes energy in the United States. It operates through three operating segments: Dominion Energy Virginia, Dominion Energy South Carolina, and Contracted Energy. The Dominion Energy Virginia segment generates, transmits, and distributes regulated electricity to approximately 2.8 million residential, commercial, industrial, and governmental customers in Virginia and North Carolina.
See Also
- Five stocks we like better than Dominion Energy
- What Do S&P 500 Stocks Tell Investors About the Market?
- Intel: Is Now the Time to Be Brave?
- P/E Ratio Calculation: How to Assess Stocks
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is a Death Cross in Stocks?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?